Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 5/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 5/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 3/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 2/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 1.00 |
| ▸ | THPO | P40225 | 2/20 | 1.00 |
| ▸ | MTOR | P42345 | 2/20 | 1.00 |
| ▸ | RAB9A | P51151 | 2/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 2/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL339982 | 0.98 | SMN1; SMN2 (1.00) | SLC6A2SLC6A4SLC6A3SIGMAR1SMN1; SMN2 | |
| SCHEMBL4199225 | 0.96 | SIGMAR1 (1.00) | SLC6A2SLC6A4SLC6A3SIGMAR1SMN1; SMN2 | |
| SCHEMBL10000765 | 0.92 | SLC6A4 (0.97) | SLC6A2SLC6A4SLC6A3SIGMAR1SMN1; SMN2 | |
| SCHEMBL6517933 | 0.90 | SIGMAR1 (0.82) | SLC6A2SLC6A4SLC6A3SIGMAR1SMN1; SMN2 | |
| SCHEMBL6254945 | 0.90 | SLC6A4 (0.90) | SLC6A2SLC6A4SLC6A3SIGMAR1SMN1; SMN2 | |
| SCHEMBL31420200 | 0.90 | SLC6A4 (0.82) | SLC6A2SLC6A4SLC6A3SIGMAR1SMN1; SMN2 | |
| Vanoxerine SCHEMBL246574 | 0.90 | SLC6A4 (1.00) | SLC6A2SLC6A4SLC6A3SIGMAR1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL11374533 | 0.89 | SLC6A4 (0.90) | SLC6A2SLC6A4SLC6A3SIGMAR1SMN1; SMN2 | |
| Vanoxerine SCHEMBL15541249 | 0.89 | SLC6A4 (1.00) | SLC6A2SLC6A4SLC6A3SIGMAR1SMN1; SMN2 | |
| Vanoxerine SCHEMBL725103 | 0.89 | SLC6A4 (1.00) | SLC6A2SLC6A4SLC6A3SIGMAR1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 181 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4618976-A1 | COMPOSITIONS AND METHODS OF TREATING NEUROLOGICAL CONDITIONS | Dri Biosciences Corporation (US) | 2025-09-24 | — | — | EP | claimed |
| US-20240398978-A1 | Compositions and Methods for Treating Dopamine Disorders | METAQOR LLC (US) | 2024-12-05 | — | — | US | claimed |
| EP-3386493-B1 | DBH INHIBITORS FOR TREATING OR PREVENTING MEMORY LOSS | UNIV BRANDEIS (US) | 2024-11-20 | — | — | EP | claimed |
| WO-2024107961-A1 | COMPOSITIONS AND METHODS OF TREATING NEUROLOGICAL CONDITIONS | DRI BIOSCIENCES CORPORATION (US) | 2024-05-23 | — | — | WO | claimed |
| EP-1485096-B1 | METHODS FOR PREVENTING OR TREATING CARDIAC ARRHYTHMIA | CHANTEST INC (US) | 2009-03-11 | — | — | EP | claimed |
| US-20040063612-A1 | Neuroprotective agents | CARBOMER, INC. | 2004-04-01 | — | — | US | claimed |
| US-12637410-B2 | Vesicular monoamine transporter-2 ligands and their use in the treatment of psychostimulant abuse | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2026-05-26 | — | — | US | disclosed |
| US-20260055059-A1 | METHODS OF TREATING MOOD DISORDERS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2026-02-26 | — | — | US | disclosed |
| US-12539298-B2 | Lobinaline N-oxides as positive allosteric modulators of the dopamine transporter with potential value in the treatment of substance abuse disorders | UNIV KENTUCKY RES FOUND (US) | 2026-02-03 | — | — | US | disclosed |
| US-20250375406-A1 | TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS AND NON-ALCOHOLIC FATTY LIVER DISEASE | VEROSCIENCE LLC (US) | 2025-12-11 | — | — | US | disclosed |
| US-12459912-B2 | Advantageous benzothiophene compositions for mental disorders or enhancement | TACTOGEN INC (US) | 2025-11-04 | — | — | US | disclosed |
| US-12454515-B2 | 2-aminoindane compounds for mental disorders or enhancement | TACTOGEN INC (US) | 2025-10-28 | — | — | US | disclosed |
| EP-4635492-A2 | TRYPTAMINES AND METHODS OF TREATING MOOD DISORDERS | Gilgamesh Pharmaceuticals, Inc. (US) | 2025-10-22 | — | — | EP | disclosed |
| US-5321000-A | Benzhydryl compounds as herbicide antidotes | MONSANTO COMPANY (US) | 1994-06-14 | — | — | US | disclosed |
| US-5162537-A | To safen acetamide herbicids used to control grassy and broadleaf weeds in rice, sorghum and wheat | MONSANTO COMPANY (US) | 1992-11-10 | — | — | US | disclosed |
| EP-0485512-A4 | SLOWLY DISSOCIATING (TIGHT BINDING) DOPAMINE, SEROTONIN OR NOREPINEPHRINE REUPTAKE INHIBITORS AS COCAINE, AMPHETAMINE AND PHENCYCLIDINE ANTAGONISTS | US HEALTH (US) | 1992-08-26 | — | — | EP | disclosed |
| EP-0485512-A1 | SLOWLY DISSOCIATING (TIGHT BINDING) DOPAMINE, SEROTONIN OR NOREPINEPHRINE REUPTAKE INHIBITORS AS COCAINE ANTAGONISTS. | THE UNITED STATES OF AMERICA as represented by the Secretary UNITED STATES DEPARTMENT OF COMMERCE (US) | 1992-05-20 | — | — | EP | disclosed |
| WO-1991001732-A1 | SLOWLY DISSOCIATING (TIGHT BINDING) DOPAMINE, SEROTONIN OR NOREPINEPHRINE REUPTAKE INHIBITORS AS COCAINE, AMPHETAMINE AND PHENCYCLIDINE ANTAGONISTS | THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, UNITED STATES DEPARTMENT OF COMMERCE (US) | 1991-02-21 | — | — | WO | disclosed |
| US-4964893-A | REDUCING INJURY TO A CROP PLANT | MONSANTO COMPANY (US) | 1990-10-23 | — | — | US | disclosed |
| US-4202896-A | DOPAMINERGIC ACTIVITY | GIST-BROCADES N.V. (NL) | 1980-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12454515-B2 | 2-aminoindane compounds for mental disorders or enhancement | AADAT, SLC1A2, TPH2 | SLC6A2 77/4885SLC6A4 153/4885SLC6A3 177/4885 |
| US-12539298-B2 | Lobinaline N-oxides as positive allosteric modulators of the dopamine transporter with potential value in the treatment of substance abuse disorders | SLC18A3, SLC18A2, SLC6A3 | SLC6A2 5/4885SLC6A4 26/4885SLC6A3 3/4885 |
| US-20260055059-A1 | METHODS OF TREATING MOOD DISORDERS | SDHB, SDHA, SORD | SLC6A2 16/4885SLC6A4 13/4885SLC6A3 25/4885 |
| US-12637410-B2 | Vesicular monoamine transporter-2 ligands and their use in the treatment of psychostimulant abuse | SLC18A2, SLC6A2, SLC6A3 | SLC6A2 2/4885SLC6A4 15/4885SLC6A3 3/4885 |
| US-20240398978-A1 | Compositions and Methods for Treating Dopamine Disorders | SLC6A3, SNCA, CLTA | SLC6A2 8/4885SLC6A4 42/4885SLC6A3 1/4885 |
| US-12459912-B2 | Advantageous benzothiophene compositions for mental disorders or enhancement | SLC6A3, CREBBP, SLC1A2 | SLC6A2 18/4885SLC6A4 21/4885SLC6A3 1/4885 |
| US-20040063612-A1 | Neuroprotective agents | GAP43, NLN, NOS3 | SLC6A2 298/4885SLC6A4 588/4885SLC6A3 327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.